Dupixent (dupilumab) / Sanofi, Regeneron - LARVOL DELTA

Biologic therapies for adult chronic urticaria: what works, what doesn't, and why. (PubMed, Expert Opin Biol Ther) - "Omalizumab remains the benchmark therapeutic agent. Dupilumab inhibits interleukin-4/interleukin-13 signaling and is approved for CSU and several type 2 and other inflammatory conditions. Remibrutinib is an oral Bruton tyrosine kinase inhibitor with efficacy across IgE-defined subgroups, supporting its relevance beyond a single proposed autoimmune endotype...Biomarkers should inform response probabilities rather than rigid prescribing decisions. Definitive disease modification remains unproven."

Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • IL13 • IL4

Safety and effectivity of dupilumab in transplant recipients with severe atopic dermatitis: A multicenter case series. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Transplantation

Moderate-to-severe chronic spontaneous urticaria is associated with increased risk of immune-mediated diseases: A population-based study. (PubMed, PLoS One) - "We propensity matched patients with ≥2 ICD-10 diagnoses of idiopathic urticaria treated with omalizumab, dupilumab, or cyclosporine (moderate-to-severe disease) to age-, sex-, race-, ethnicity-, comorbidity-, and family history-matched counterparts who were never treated with biologics or cyclosporine (mild disease). Patients with moderate-to-severe CSU had a significantly increased risk of developing rheumatoid arthritis OR=1.34 (95% CI: 1.12 to 1.60, p = 0.001) and Sjögren's syndrome OR=1.04 (1.63-2.56, p < 0.0001), after adjusting for clinical factors and multiple hypothesis testing (Bonferroni's alpha ≤0.00333). Moderate-to-severe CSU is associated with an increased risk of rheumatoid arthritis and Sjögren's syndrome compared to mild CSU."

Journal • Retrospective data • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome • Urticaria

Prospective reflectance confocal microscopy monitoring in dupilumab-treated atopic dermatitis. (PubMed, J Eur Acad Dermatol Venereol) - "Persistent RCM abnormalities, particularly epidermal disorganization, spongiosis and dilated vessels, were observed at week 24, even among EASI-75 responders. These findings suggest that clinical response to dupilumab may not always coincide with complete microstructural normalization and that RCM may provide complementary information beyond clinical outcomes."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics

Immunopathogenic Endotypes of Asthma: From Type 2 and Non-Type 2 Inflammation to Precision Therapeutic Strategies. (PubMed, J Asthma) - "Depending on type of inflammation, eosinophilic (anti-IL-5 (mepolizumab) and mixed inflammation (dupilumab/tezepelumab) and high IgE (omalizumab) biomarkers are pivotal in stratifying phenotypes, predicting exacerbation, and informing targeted biologics, including anti-IL-5 (mepolizumab) and dupilumab/tezepelumab, respectively. This synthesis heralds a paradigm shift of empirical symptom control to personalized interventions, reduction of exacerbations, lessening of overtreatment, and the identification of new targets in multi-omics era to overcome the unmet needs of severe, steroid-resistant asthma."

Journal • Review • Allergy • Asthma • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • IL33 • IL4 • IL5

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. (PubMed, Eur J Clin Invest) - "COPD management is evolving toward precision medicine, guided by inflammatory phenotypes, biomarkers, and individualised risk profiles. Continued investigation into targeted biologics, anti-inflammatory agents, and incorporating biomarkers into clinical practice may improve outcomes and reduce disease burden."

Biomarker • Journal • Review • Cardiovascular • Chronic Obstructive Pulmonary Disease • Cognitive Disorders • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL33

Dupilumab in Paediatric Netherton Syndrome: Two Case Reports and a Review of the Literature. (PubMed, Australas J Dermatol) - "To address this gap and provide insights into the long-term trajectory of dupilumab treatment in this population, we report two cases of NS treated with dupilumab over 20 and 25 months. This paper demonstrates that dupilumab may be a relatively safe and potentially effective option for targeting Th2-mediated inflammation though its overall sustained effectiveness may be variable."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Inflammation • Pediatrics • Vitiligo

Influence of newly initiated biologic therapy on the dose of ICS therapy - Data from the German Asthma Net. (PubMed, J Allergy Clin Immunol Pract) - "ICS reduction was associated with improved patient-reported outcomes without worsening exacerbations, lung function or FeNO."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Dupilumab Targeting IL-4/IL-13 Pathway Improves RTK- and PD-1-Inhibitor-Related Cutaneous Adverse Drug Reactions. (PubMed, Scand J Immunol) - No abstract available

Adverse drug reaction • Journal • IL13 • IL4

Precision Medicine in Overlap Syndrome (COPD-Obstructive Sleep Apnea): From Phenotypes and Endotypes to Treatable Traits. (PubMed, Adv Respir Med) - "Endotyping of OVS may provide a framework for moving beyond a uniform therapeutic approach toward more individualized management based on the dominant underlying biological mechanism. Randomized clinical trials focusing on endotypic stratification and OVS cohorts remain research priorities."

Biomarker • Clinical • Journal • Review • Cardiovascular • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Immunology • Inflammation • Obesity • Obstructive Sleep Apnea • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection. (PubMed, Antibodies (Basel)) - "Between February 2024 and September 2025 the landscape changed: dupilumab (anti-IL-4Rα) and the first oral Bruton tyrosine kinase (BTK) inhibitor, remibrutinib, were approved for CSU; omalizumab biosimilars reached the market; the higher-affinity anti-IgE antibody ligelizumab was discontinued; and the investigational anti-KIT antibody barzolvolimab advanced to phase 3-creating new therapeutic opportunities for non-responders while leaving the choice among these second-line options unresolved by current guidelines. Current evidence appears to support omalizumab as first-line, with mechanism-guided second-line choices conditioned on endotype, comorbidity, prior biologic exposure and safety. The complexity of CSU and the incomplete response to currently available therapies support a patient-tailored approach to treatment selection."

Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma. (PubMed, J Allergy Clin Immunol Pract) - "Dupilumab was associated with a modestly higher, but overall infrequent, risk of OAEs than IL-5 inhibitors in asthma over 6 months (2.6% vs 2.1%), a rate substantially lower than the 8-28% previously reported in AD populations. This risk, driven primarily by conjunctivitis, was most pronounced among younger adults, men, and patients with comorbid AD, suggesting that AD may also contribute to this adverse effect. Continued ocular monitoring is warranted, particularly in these subgroups."

Journal • Allergic Rhinitis • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Hypereosinophilic Syndrome • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome • IL5

Prescribing characteristics of asthma biologics used in an adult cystic fibrosis clinic (NACFC 2026) - "The most common initial biologic used was dupilumab with 25 patients initiated on this, with 5 started on benralizumab, 3 on omalizumab and 1 on mepolizumab. Given their favorable safety data, the potential risks of inhaled steroids in cystic fibrosis, and the high prevalence of asthma and T2 inflammation in cystic fibrosis, asthma biologics represent an attractive treatment option in cystic fibrosis. More research is needed, however, to determine their safety, efficacy and the optimal biomarkers to predict response in cystic fibrosis."

Clinical • Allergic Bronchopulmonary Aspergillosis • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Eosinophilic Esophagitis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pruritus • Pulmonary Disease • Respiratory Diseases • Sinusitis

COMPARATIVE DRUG SURVIVAL, REASONS FOR DISCONTINUATION, AND PREDICTORS OF TREATMENT PERSISTENCE FOR DUPILUMAB AND UPADACITINIB IN ATOPIC DERMATITIS: A 297-PATIENT MULTICENTRE AUSTRALIAN STUDY (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison (EADV 2026) - No abstract available

Clinical • Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

One Stone, Two Birds: Successful Treatment of Generalized Granuloma Annulare and Urticarial Vasculitis with Dupilumab (EADV 2026) - No abstract available

Dermatology • Immunology • Rare Diseases • Urticaria • Vasculitis

Refractory chronic actinic dermatitis successfully treated with dupilumab (EADV 2026) - No abstract available

Dermatitis • Dermatology • Immunology

Complete Remission of Dupilumab-Refractory Erythrodermic Chronic Actinic Dermatitis with Upadacitinib (EADV 2026) - No abstract available

Clinical • Dermatitis • Dermatology • Immunology

Improvement in Nasal Eosinophilia in Pediatric Chronic Rhinitis on Dupilumab: A Case Report (AAO-HNSF 2026) - "We present a unique case of subjective and objective improvement of rhinologic disease after dupilumab that suggests biologics may benefit select pediatric cases with nasal eosinophilia who fail standard therapy. While nasal cytology is not routinely used as an outcome measure in pediatric CRSwNP, this case highlights its potential as a low-cost, easily repeatable tool to characterize inflammation and track treatment response over time. These findings support the growing consideration of biologics as adjunctive therapy in pediatric nasal polyposis and suggest that nasal cytology may help guide and monitor such interventions in clinical practice."

Case report • Clinical • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Immunology • Infectious Disease • Inflammation • Nasal Polyps • Otorhinolaryngology • Pediatrics • Respiratory Diseases • Sinusitis • IL13 • IL4

Stapokibart for Facial-Predominant AD-Like Dermatoses: A Retrospective Real-World Case Series Highlighting Response Heterogeneity. (PubMed, Clin Cosmet Investig Dermatol) - "In this small case series, rapid improvement was observed in all three patients with a well-supported facial-predominant AD phenotype, whereas atypical or incompletely characterized eruptions showed greater diagnostic complexity and variable outcomes. These preliminary observations support further investigation of stapokibart in facial-predominant AD while underscoring the need for careful phenotyping before IL-4Rα blockade."

Heterogeneity • Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Dermatomyositis • Immunology • Inflammation • Myositis • Pruritus • Rosacea

Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis. (PubMed, J Allergy Clin Immunol) - "In patients with asthma and ABPA, dupilumab significantly improved lung function compared with placebo, reduced severe respiratory exacerbations, and was well tolerated."

Journal • Allergic Bronchopulmonary Aspergillosis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL4R

Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "This case adds to emerging evidence that dupilumab may be considered in carefully selected pediatric patients with severe, treatment-refractory AA and features suggestive of type 2 immune involvement. Because minoxidil was continued concomitantly, baseline inflammatory activity was limited, and spontaneous regrowth cannot be excluded, the clinical improvement cannot be attributed to dupilumab alone."

Journal • Alopecia • Dermatology • Immunology • Inflammation • Pediatrics

Real-world effectiveness of T2-targeted biologics in patients with chronic obstructive pulmonary disease (COPD) (ERS 2026) - " This retrospective, monocentric study at Foch Hospital included COPD patientstreated for ≥ 3 months with Th2-targeted biologics (benralizumab, dupilumab, mepolizumab,omalizumab, or tezepelumab) between 2018 and 2025. T2-targeted biologics significantly reduce exacerbation frequency and OCS usein COPD patients, regardless of an associated asthma phenotype."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases

Do baseline characteristics predict abolition of airway hyperresponsiveness with biologics in severe uncontrolled asthma? (ERS 2026) - "Methods This post hoc analysis included patients with severe uncontrolled type 2 high asthma treated with 3 months of either benralizumab or dupilumab (EudraCT 2019–003763-22 and EudraCT 2021-005593-25). This in turn may help in adopting a tailored approach to biologics. Further long term studies are required to assess if abolition of AHR with biologics relates to clinical remission."

Asthma • Immunology • Respiratory Diseases

The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Hospital Italiano de Buenos Aires | Active, not recruiting ➔ Completed | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology